These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 34314844)
1. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Zhang M; Wei W; Peng C; Ma X; He X; Zhang H; Zhou M Bioorg Med Chem Lett; 2021 Oct; 49():128286. PubMed ID: 34314844 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy. Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma. Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167 [TBL] [Abstract][Full Text] [Related]
4. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells. Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324 [TBL] [Abstract][Full Text] [Related]
7. Discovering novel derivatives of STAT3 and HDAC inhibitors with anti-tumor activity. Yang Y; Pu Y; Huang X; Liao M; Zhang Y Chem Biol Drug Des; 2024 Jul; 104(1):e14593. PubMed ID: 39056367 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2- Xing K; Zhang J; Han Y; Tong T; Liu D; Zhao L Molecules; 2020 Sep; 25(18):. PubMed ID: 32967084 [TBL] [Abstract][Full Text] [Related]
9. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity. Liu M; Gao S; Liang T; Qiu X; Yang X; Fang H; Hou X J Med Chem; 2022 Sep; 65(18):12200-12218. PubMed ID: 36097406 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents. Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Thieno[2,3- Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186 [TBL] [Abstract][Full Text] [Related]
13. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor. Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening. Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683 [TBL] [Abstract][Full Text] [Related]
17. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920 [TBL] [Abstract][Full Text] [Related]
18. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326 [TBL] [Abstract][Full Text] [Related]
19. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. Dong Y; Hu H; Sun Y; Qin M; Gong P; Hou Y; Zhao Y Bioorg Med Chem Lett; 2020 Dec; 30(23):127610. PubMed ID: 33045329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]